Clinical studies in spinal cord injury: moving towards successful trials

References

• NSCISC. Spinal cord injury. Facts and figures at a glance. J Spinal Cord Med 2005; 28: 379–380
   PubMedGoogle Scholar
• Tator C H, Duncan E G, Edmonds V E, Lapczak L I, Andrews D F. Comparison of surgical and conservative management in 208 patients with acute spinal cord injury. Can J Neurol Sci 1987; 14: 60–69
   PubMed Web of Science ®Google Scholar
• Tator C H. Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 2006; 59: 957–982, discussion 982 – 987
   PubMed Web of Science ®Google Scholar
• Ramòn y Cajal S. Degeneration and regeneration of the nervous system. Oxford University Press, London 1928
   Google Scholar
• Bareyre F M, Kerschensteiner M, Raineteau O, et al. The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. Nat Neurosci 2004; 7: 269–277
   PubMed Web of Science ®Google Scholar
• McKeon R J, Schreiber R C, Rudge J S, Silver J. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J Neurosci 1991; 11: 3398–3411
   PubMed Web of Science ®Google Scholar
• Bundesen L Q, Scheel T A, Bregman B S, Kromer L F. Ephrin-B2 and EphB2 regulation of astrocyte-meningeal fibroblast interactions in response to spinal cord lesions in adult rats. J Neurosci 2003; 23: 7789–7800
   PubMed Web of Science ®Google Scholar
• Pasterkamp R J, Anderson P N, Verhaagen J. Peripheral nerve injury fails to induce growth of lesioned ascending dorsal column axons into spinal cord scar tissue expressing the axon repellent Semaphorin3A. Eur J Neurosci 2001; 13: 457–471
   PubMed Web of Science ®Google Scholar
• GrandPre T, Nakamura F, Vartanian T, Strittmatter S M. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000; 403(6768)439–444
   PubMed Web of Science ®Google Scholar
• Chen M S, Huber A B, van der Haar M E, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000; 403(6768)434–439
   PubMed Web of Science ®Google Scholar
• Wang K C, Koprivica V, Kim J A, et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002; 417(6892)941–944
   PubMed Web of Science ®Google Scholar
• Bracken M B, Collins W F, Freeman D F, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984; 251: 45–52
   PubMed Web of Science ®Google Scholar
• Bracken M B, Shepard M J, Collins W F, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990; 322: 1405–1411
   PubMed Web of Science ®Google Scholar
• Bracken M B, Shepard M J, Holford T R, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997; 277: 1597–1604
   PubMed Web of Science ®Google Scholar
• Coleman W P, Benzel D, Cahill D W, et al. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord 2000; 13(3)185–199
   PubMedGoogle Scholar
• Hurlbert R J. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000; 93(1 Suppl)1–7
   PubMed Web of Science ®Google Scholar
• Short D J, El Masry W S, Jones P W. High dose methylprednisolone in the management of acute spinal cord injury—a systematic review from a clinical perspective. Spinal Cord 2000; 38(5)273–286
   PubMed Web of Science ®Google Scholar
• Geisler F H, Dorsey F C, Coleman W P. Recovery of motor function after spinal-cord injury—a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 1991; 324(26)1829–1838
   PubMed Web of Science ®Google Scholar
• Geisler F H, Coleman W P, Grieco G, Poonian D. The Sygen multicenter acute spinal cord injury study. Spine 2001; 26(24 Suppl)S87–S98
   PubMed Web of Science ®Google Scholar
• Steeves J, Fawcett J, Tuszynski M. Report of international clinical trials workshop on spinal cord injury February 20 – 21, 2004, Vancouver, Canada. Spinal Cord 2004; 42(10)591–597
   PubMedGoogle Scholar
• Lepeintre J F, D'Arbigny P, Mathe J F, et al. Neuroprotective effect of gacyclidine. A multicenter double-blind pilot trial in patients with acute traumatic brain injury. Neurochirurgie 2004; 50(2 – 3 Pt 1)83–95
   PubMed Web of Science ®Google Scholar
• Lee S M, Yune T Y, Kim S J, et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003; 20: 1017–1027
   PubMed Web of Science ®Google Scholar
• Stirling D P, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004; 24: 2182–2190
   PubMed Web of Science ®Google Scholar
• Wells J E, Hurlbert R J, Fehlings M G, Yong V W. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003; 126(Pt 7)1628–1637
   PubMed Web of Science ®Google Scholar
• Kwon B K, Fisher C G, Dvorak M F, Tetzlaff W. Strategies to promote neural repair and regeneration after spinal cord injury. Spine 2005; 30(17 Suppl)S3–S13
   Google Scholar
• Hansebout R R, Blight A R, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993; 10: 1–18
   PubMed Web of Science ®Google Scholar
• Hayes K C, Potter P J, Wolfe D L, et al. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury. J Neurotrauma 1994; 11: 433–446
   PubMed Web of Science ®Google Scholar
• Potter P J, Hayes K C, Segal J L, et al. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma 1998; 15(10)837–849
   PubMed Web of Science ®Google Scholar
• DeForge D, Nymark J, Lemaire E, et al. Effect of 4-aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial. Spinal Cord 2004; 42(12)674–685
   PubMed Web of Science ®Google Scholar
• van der Bruggen M A, Huisman H B, Beckerman H, et al. Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol 2001; 248(8)665–671
   PubMed Web of Science ®Google Scholar
• Cardenas D D, Ditunno J, Graziani V, et al. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord 2007; 45(2)158–168
   PubMed Web of Science ®Google Scholar
• Pitts L H, Ross A, Chase G A, Faden A I. Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries. J Neurotrauma 1995; 12: 235–243
   PubMed Web of Science ®Google Scholar
• Reier P J, Stokes B T, Thompson F J, Anderson D K. Fetal cell grafts into resection and contusion/compression injuries of the rat and cat spinal cord. Exp Neurol 1992; 115: 177–188
   PubMed Web of Science ®Google Scholar
• Falci S, Holtz A, Akesson E, et al. Obliteration of a posttraumatic spinal cord cyst with solid human embryonic spinal cord grafts: first clinical attempt. J Neurotrauma 1997; 14(11)875–884
   PubMed Web of Science ®Google Scholar
• Wirth E D, 3rd, Reier P J, Fessler R G, et al. Feasibility and safety of neural tissue transplantation in patients with syringomyelia. J Neurotrauma 2001; 18: 911–929
   PubMed Web of Science ®Google Scholar
• Rapalino O, Lazarov-Spiegler O, Agranov E, et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 1998; 4: 814–821
   PubMed Web of Science ®Google Scholar
• Popovich P G, Guan Z, McGaughy V, et al. The neuropathological and behavioural consequences of intraspinal microglial/macrophage activation. J Neuropathol Exp Neurol 2002; 61: 623–633
   PubMed Web of Science ®Google Scholar
• Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine 2005; 3(3)173–181
   PubMed Web of Science ®Google Scholar
• Cheng H, Cao Y, Olson L. Spinal cord repair in adult paraplegic rats: partial restoration of hind limb function. Science 1996; 273(5274)510–513
   PubMed Web of Science ®Google Scholar
• Lee Y S, Hsiao I, Lin V W. Peripheral nerve grafts and aFGF restore partial hindlimb function in adult paraplegic rats. J Neurotrauma 2002; 19: 1203–1216
   PubMed Web of Science ®Google Scholar
• Levi A D, Dancausse H, Li X, et al. Peripheral nerve grafts promoting central nervous system regeneration after spinal cord injury in the primate. J Neurosurg 2002; 96(2 Suppl)197–205
   PubMed Web of Science ®Google Scholar
• Cheng H, Liao K K, Liao S F, Chuang T Y, Shih Y H. Spinal cord repair with acidic fibroblast growth factor as a treatment for a patient with chronic paraplegia. Spine 2004; 29(14)E284–E288
   Google Scholar
• Raisman G. Specialized neuroglial arrangement may explain the capacity of vomeronasal axons to reinnervate central neurons. Neuroscience 1985; 14: 237–254
   PubMed Web of Science ®Google Scholar
• Li Y, Field P M, Raisman G. Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells. Science 1997; 277(5334)2000–2002
   PubMed Web of Science ®Google Scholar
• Li Y, Decherchi P, Raisman G. Transplantation of olfactory ensheathing cells into spinal cord lesions restores breathing and climbing. J Neurosci 2003; 23: 727–731
   PubMed Web of Science ®Google Scholar
• Lu J, Feron F, Ho S M, Mackay-Sim A, Waite P M. Transplantation of nasal olfactory tissue promotes partial recovery in paraplegic adult rats. Brain Res 2001; 889: 344–357
   PubMed Web of Science ®Google Scholar
• Lu J, Feron F, Mackay-Sim A, Waite P M. Olfactory ensheathing cells promote locomotor recovery after delayed transplantation into transected spinal cord. Brain 2002; 125(Pt 1)14–21
   PubMed Web of Science ®Google Scholar
• Ramer L M, Richter M W, Roskams A J, Tetzlaff W, Ramer M S. Peripherally-derived olfactory ensheathing cells do not promote primary afferent regeneration following dorsal root injury. Glia 2004; 47: 189–206
   PubMed Web of Science ®Google Scholar
• Riddell J S, Enriquez-Denton M, Toft A, Fairless R, Barnett S C. Olfactory ensheathing cell grafts have minimal influence on regeneration at the dorsal root entry zone following rhizotomy. Glia 2004; 47: 150–167
   PubMed Web of Science ®Google Scholar
• Feron F, Perry C, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 2005; 128(Pt 12)2951–2960
   PubMed Web of Science ®Google Scholar
• Lima C, Pratas-Vital J, Escada P, et al. Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J Spinal Cord Med 2006; 29(3)191–203, discussion 204 – 206
   PubMed Web of Science ®Google Scholar
• Huang H, Chen L, Wang H, et al. Influence of patients' age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin Med J (Engl) 2003; 116: 1488–1491
   PubMed Web of Science ®Google Scholar
• Dobkin B H, Curt A, Guest J. Cellular transplants in China: observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil Neural Repair 2006; 20: 5–13
   PubMed Web of Science ®Google Scholar
• Hofstetter C P, Schwarz E J, Hess D, et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci USA 2002; 99: 2199–2204
   PubMed Web of Science ®Google Scholar
• Koda M, Okada S, Nakayama T, et al. Hematopoietic stem cell and marrow stromal cell for spinal cord injury in mice. Neuroreport 2005; 16: 1763–1767
   PubMed Web of Science ®Google Scholar
• Koshizuka S, Okada S, Okawa A, et al. Transplanted hematopoietic stem cells from bone marrow differentiate into neural lineage cells and promote functional recovery after spinal cord injury in mice. J Neuropathol Exp Neurol 2004; 63: 64–72
   PubMed Web of Science ®Google Scholar
• Reier P J. Cellular transplantation strategies for spinal cord injury and translational neurobiology. NeuroRx 2004; 1: 424–451
   PubMedGoogle Scholar
• McDonald J W, Liu X Z, Qu Y, et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med 1999; 5: 1410–1412
   PubMed Web of Science ®Google Scholar
• Cummings B J, Uchida N, Tamaki S J, et al. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc Natl Acad Sci USA 2005; 102: 14069–14074
   PubMed Web of Science ®Google Scholar
• Schnell L, Schwab M E. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 1990; 343(6255)269–272
   PubMed Web of Science ®Google Scholar
• Bregman B S, Kunkel-Bagden E, Schnell L, et al. Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature 1995; 378(6556)498–501
   PubMed Web of Science ®Google Scholar
• Schweigreiter R, Bandtlow C E. Nogo in the injured spinal cord. J Neurotrauma 2006; 23: 384–396
   PubMed Web of Science ®Google Scholar
• Freund P, Schmidlin E, Wannier T, et al. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat Med 2006; 12: 790–792
   PubMed Web of Science ®Google Scholar
• GrandPre T, Li S, Strittmatter S M. Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 2002; 417(6888)547–551
   PubMed Web of Science ®Google Scholar
• Li S, Strittmatter S M. Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J Neurosci 2003; 23: 4219–4227
   PubMed Web of Science ®Google Scholar
• Thuret S, Moon L D, Gage F H. Therapeutic interventions after spinal cord injury. Nat Rev Neurosci 2006; 7(8)628–643
   PubMed Web of Science ®Google Scholar
• Dergham P, Ellezam B, Essagian C, et al. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 2002; 22: 6570–6577
   PubMed Web of Science ®Google Scholar
• Fournier A E, Takizawa B T, Strittmatter S M. Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci 2003; 23: 1416–1423
   PubMed Web of Science ®Google Scholar
• Moon L D, Asher R A, Rhodes K E, Fawcett J W. Regeneration of CNS axons back to their target following treatment of adult rat brain with chondroitinase ABC. Nat Neurosci 2001; 4: 465–466
   PubMed Web of Science ®Google Scholar
• Bradbury E J, Moon L D, Popat R J, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002; 416(6881)636–640
   PubMed Web of Science ®Google Scholar
• Fouad K, Schnell L, Bunge M B, et al. Combining Schwann cell bridges and olfactory-ensheathing glia grafts with chondroitinase promotes locomotor recovery after complete transection of the spinal cord. J Neurosci 2005; 25: 1169–1178
   PubMed Web of Science ®Google Scholar
• Anderson D K, Beattie M, Blesch A, et al. Recommended guidelines for studies of human subjects with spinal cord injury. Spinal Cord 2005; 43(8)453–458
   PubMed Web of Science ®Google Scholar
• Fawcett J W, Curt A, Steeves J D, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007; 45(3)190–205
   PubMed Web of Science ®Google Scholar
• Lammertse D, Tuszynski M H, Steeves J D, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design. Spinal Cord 2007; 45(3)232–242
   PubMed Web of Science ®Google Scholar
• Steeves J D, Lammertse D, Curt A, et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 2007; 45(3)206–221
   PubMed Web of Science ®Google Scholar
• Tuszynski M H, Steeves J D, Fawcett J W, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord 2007; 45: 222–231
   PubMed Web of Science ®Google Scholar
• Frankel H L, Hancock D O, Hyslop G, et al. The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. I. Paraplegia 1969; 7(3)179–192
   PubMedGoogle Scholar
• Watts J. Controversy in China. Lancet 2005; 365(9454)109–110
   PubMed Web of Science ®Google Scholar
• Guest J, Herrera L P, Qian T. Rapid recovery of segmental neurological function in a tetraplegic patient following transplantation of fetal olfactory bulb-derived cells. Spinal Cord 2006; 44(3)135–142
   PubMed Web of Science ®Google Scholar
• Blight A R, Tuszynski M H. Clinical trials in spinal cord injury. J Neurotrauma 2006; 23: 586–593
   PubMed Web of Science ®Google Scholar
• Cohen M, Sheehan T, Herbison G. Content validity and reliability of the international standards for neurological classification of spinal cord injury. Top Spinal Cord Inj Rehab 1996; 1: 15–31
   Google Scholar